Covalon Reports Fifth Consecutive Quarter of Positive Earnings
MISSISSAUGA, Ontario, May 28, 2025--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2025 second quarter results for the period ended March 31, 2025, along with a number of important recent achievements and highlights.
Brent Ashton, Covalon's Chief Executive Officer, reported, "In the past few months, the Covalon team has delivered on several of our key priorities that have led to expanded sales with new and existing customers, new agreements with key strategic partners, and exciting new clinical evidence generation.
In the first six months of our 2025 fiscal year, Covalon has:
Grown revenue by 21%,
Grown Gross Profit by 12%
Reduced Operating Expenses by 8%
Increased Adjusted EBITDA by 57%
As stated last quarter, we fully anticipated our U.S. Advanced Wound Care sales channel to have a sequential quarter decline in Q2. This is not consequential, as we have a clear line of sight via in-house orders, forecasts and recent strategic partner sell out trends, to a strong Q3 and second half.
Covalon recently signed a major distribution agreement with our longstanding strategic partner, Paul Hartmann USA, for ColActive Plus® and ColActive Plus® with Silver advanced wound care dressings. Covalon's U.S. Advanced Wound Care sales channel has been an important growth driver for the Company, and our first half of FY'25 was double the revenue from the same period two years ago.
Our U.S. Vascular Access and Surgical Consumables sales channel had excellent sequential quarterly growth of 19%, and year to date is up 46% vs. the prior year, led by significant growth from Covalon's VALGuard® Vascular Access Line Guard product. New clinical evidence on Covalon's VALGuard® will be presented at two prestigious scientific meetings in the fall and is advancing through the publication process in a major, well-regarded academic journal. This will be a significant accelerator to the surge in adoption that we have seen with major U.S. hospitals.
We have also made significant headway in our International sales channel, and our Q2 revenue of $2.3 million marked our highest quarterly revenue for International in more than five years, and has grown 44% year to date.
In a volatile and complex global trade environment, Covalon's North American-centric manufacturing strategy has yielded no tariff-related costs to date, and the Company sees the current tariff environment as a competitive advantage.
Covalon is in a stronger position than it has ever been, with profitable operations and a clean balance sheet with more than $18 million in cash and no debt. We have retained a highly regarded financial and strategic advisor to identify merger and acquisition opportunities and unlock value for all shareholders. Our accelerated focus on market development is generating exciting results. I see a clear path for Covalon to become a major player in the lucrative healthcare spaces we operate in."
Q2 FY'25 Financial Highlights
Revenue of $7.6 million led by strong growth in the U.S. Vascular Access and Surgical Consumables business as well as the International business
Adjusted EBITDA of $0.6 million – Covalon's 5th consecutive quarter of profitability
Strong free cash flow generation of $0.6 million
Recent Covalon Achievements and Highlights
Exciting results from an impactful clinical evidence study by a nursing research team at a large United States children's hospital have been selected for presentation at two prestigious scientific meetings this fall and are advancing through the final stages of the publication process in a major, well-regarded academic journal. Shared via the following press release:https://ir.covalon.com/news/news-details/2025/Covalon-Announces-Exciting-New-Clinical-Research-Evaluating-VALGuard-Vascular-Access-Line-Guard/default.aspx
Signed a new distribution agreement with longstanding strategic partner Paul Hartmann USA for ColActive Plus® and ColActive Plus® with Silver advanced wound care dressings.
The Company initiated work with Origin Merchant Partners to pursue strategic options to maximize shareholder value and expand the reach of our innovative medical technologies. Shared via the following press release:https://ir.covalon.com/news/news-details/2025/Covalon-Retains-Financial-and-Strategic-Advisor-to-Advise-on-Shareholder-Value-Enhancing-Opportunities/default.aspx
Promoted Kim Crooks to be Chief Operating Officer and join Covalon's Board of Directors. Promoted Dr. Kate Evely to be Vice President of Clinical Affairs. Both Ms. Crooks and Dr. Evely have been instrumental in the recent success of the company. Ms. Crooks' announcement can be found athttps://ir.covalon.com/news/news-details/2025/Covalon-Announces-Promotion-of-Kim-Crooks-to-Chief-Operating-Officer-and-Appointment-to-Board-of-Directors/default.aspx
Successful investor presentations and meetings at Planet Microcap Showcase: Vegas 2025 and the 2025 Bloom Burton Healthcare Investor Conference. Presentation content and audio can be found here:https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/guest_book?session_id=HcJChMRczMNFyjGQ8jTLb3
The Company has successfully navigated the volatile global tariff environment with no additional tariff-related costs in Q2, FY'25. Based on the current tariff environment, Covalon does not anticipate any material future tariff costs related to the 2025 tariff changes. As the largest North American manufacturer of collagen wound care dressings, the Company sees the current tariff environment as a competitive advantage for its U.S. Advanced Wound Care business.
Conference Call Scheduled
A conference call and webcast to discuss Covalon's fiscal 2025 Q2 financial results will be held on Wednesday, May 28 at 8:30am Eastern Time. To view, listen to, and participate in the live webcast, please follow the link below:
https://events.q4inc.com/attendee/971812521
To listen and participate via the conference call, please dial:
North American Toll-Free: 1-800-549-8228Local (Toronto): 289-819-1520Local (New York): 646-564-2877Conference ID: 92114
Participants will be able to ask questions of Company management during the Q&A portion of the conference call.
A recording of the call will also be available on www.covalon.com under Financials on the Investors tab.
Q2 Financial Overview
For the three-month period ending March 31, 2025:
Total revenue decreased to $7,585,968 compared to $8,388,022 in the same period of the prior year. The decrease in product revenue was primarily driven by a normalization of channel inventory for one of the Company's Advanced Wound Care U.S. strategic partners.
The Company reported a gross margin of 55% for the period, compared to 63% in the same period of the prior year. The year-over-year decrease in gross margin was primarily driven by changes in geographic and product mix.
The operating expenses were relatively consistent at $3,857,686, compared to $3,827,704 in the same period of the prior period.
The operations department covers expenses related to quality control, quality assurance, production, and regulatory activities. Operations expenses increased slightly to $451,471 compared to $423,239 in the same period of the prior year. This increase was primarily due to higher employee training costs incurred in the current period, which helped to strengthen operational efficiency and compliance with regulatory standards.
Research and development expenses decreased to $320,459 compared to $450,510 in the same period of the prior year primarily due to lower patent & trademark costs as the costs can vary by quarter and fiscal year due to the timing and region of the renewals.
Sales and marketing expenses were flat at $1,250,162, compared to $1,262,960 in the same period of the prior year. The Company continues to optimize sales and marketing strategies to accelerate demand for the company's products.
General and administrative expenses increased to $1,835,594 compared to $1,690,995 in the same period of the prior year, reflecting higher professional service fees. Wages, benefits, and consulting fees (for all departments) included non-cash share-based compensation expenses of $65,540, down from $81,464 in the prior year. These costs reflect outstanding stock options and deferred share units (DSUs) and their respective fair values.
For the six-month period ending March 31, 2024:
Total revenue increased to $15,751,948 compared to $13,076,667 in the same period of the prior year, with double digit growth in the 3 main sales channels the company is focused on – the U.S. Advanced Wound Care sales channel, the U.S. Vascular Access and Surgical Consumables sales channel and the International sales channel.
Gross Margin decreased to 58% compared to 62% in the same period for the prior year. During the six months ended March 31, 2025, the Company recorded a $114,645 release in inventory provision due to revised obsolescence estimates, compared to an inventory provision of $482,095 recorded during the six months ended March 31, 2024. Gross margin fluctuates as a result of the mix of products sold in any given quarter, or year, by product type and geography.
Operating expenses decreased to $7,537,484 compared to $8,147,756 in the same period of the prior year. The majority of this decrease, is attributable to reduced sales and marketing expenses. Additional spending reductions were realized across operations, research and development, and general and administrative functions, reflecting the Company's continued focus on cost efficiency and disciplined expense management.
Operations expenses decreased to $822,540 from $1,053,952 in the same period of the prior year. The reduction was primarily attributable to the timing of expenses related to product development initiatives that were recognized in the prior year.
Research and development expenses decreased to $693,798 compared to $761,921 in the same period for the prior year, mainly due to lower patent and trademark costs.
Sales and marketing costs decreased to $2,459,982 compared to $2,909,263 in the same period of the prior year, due primarily to lower staffing levels.
General and administrative expenses increased to $3,561,164 compared to $3,422,620 in the same period in the prior year, due primarily to higher spending on professional service fees.
Wages, benefits, and consulting fees (for all departments) include a non-cash compensation expense of $156,063, down from $197,393 in the prior year. These costs reflect outstanding stock options and deferred share units (DSUs) and their respective fair values.
Statement of Operations
The following audited table presents Covalon's consolidated statements of operations for the three-month and six-month periods ended March 31, 2025, and 2024.
Three months endedMarch 31,
Six months endedMarch 31,
2025
2024
2025
2024
Revenue
Product
$7,585,968
$8,388,022
$15,663,908
$12,963,789
Development and consulting services
-
-
5,826
56,640
Licensing and royalty fees
-
25,588
82,214
56,238
Total revenue
7,585,968
8,413,610
15,751,948
13,076,667
Cost of sales
3,446,462
3,103,148
6,617,976
4,917,668
Gross profit
4,139,506
5,310,462
9,133,972
8,158,999
Operating expenses
Operations
451,471
423,239
822,540
1,053,952
Research and development activities
320,459
450,510
693,798
761,921
Sales, marketing and agency fees
1,250,162
1,262,960
2,459,982
2,909,263
General and administrative
1,835,594
1,690,995
3,561,164
3,422,620
3,857,686
3,827,704
7,537,484
8,147,756
Finance expenses (income)
(147,319)
22,340
(188,387)
12,376
Loss/(gain) on finance lease receivable
-
-
149,690
(610,008)
Net income
$429,139
$1,460,418
$1,635,185
$608,875
Other comprehensive income (loss)
Amount that may be reclassified to profit or loss
Foreign currency translation adjustment
(40,155)
576,178
1,810,299
188,905
Total comprehensive income
$388,984
$2,036,596
$3,445,484
$797,780
Income per common share
Basic income per share (Note 16)
$0.02
$0.06
$0.06
$0.02
Diluted income per share (Note 16)
$0.02
$0.06
$0.06
$0.02
Non-GAAP Financial Measures
This press release makes reference to certain non-GAAP measures. These measures are not recognized or defined measures under IFRS Accounting Standards, do not have standardized meaning prescribed by IFRS Accounting Standards and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional financial information to complement those IFRS Accounting Standards measures by providing further understanding of our results of operations from management's perspective. Accordingly, these measures should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS Accounting Standards. The non-GAAP financial measures, adjustments, and reasons for adjustments should be carefully evaluated as these measures have limitations as analytical tools and should not be used in substitution for an analysis of the Company's results under IFRS Accounting Standards. We use non-GAAP measures including "Adjusted Gross Margin" and "Adjusted EBITDA" to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS Accounting Standards measures. We believe that securities analysts, investors and other interested parties frequently use non-GAAP measures in the evaluation of issuers. Our management also uses non-GAAP measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. The following non-GAAP financial measures are presented in this news release, and a description of the calculation for each measure is included below:
Adjusted Gross Margin is defined as gross profit before operating expenses, plus depreciation and amortization included in cost of sales, plus inventory provision amounts.
Adjusted EBITDA as earnings (loss) before interest expense (income), depreciation and amortization, stock-based compensation, inventory provisions (reversals), gain (loss) on finance lease receivable, and loss (gain) on disposal of property and equipment.
You should also be aware that the Company may recognize income or incur expenses in the future that are the same as, or similar to some of the adjustments in these non-GAAP financial measures. Because these non-GAAP financial measures may be defined differently by other companies in our industry, our definitions of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies, thereby diminishing their utility.
The table below provides a reconciliation of gross profit before operating expenses under IFRS Accounting Standards in the consolidated financial statements to Adjusted Gross Margin for the three-month and six-month periods ended March 31, 2025, and 2024. Management believes that Adjusted Gross Margin is useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows from period to period. The adjusting items below are considered to be outside of the Company's core operating results, and these items can distort the trends associated with the Company's ongoing performance, even though some of those expenses may recur.
Three months endedMarch 31,
Six months endedMarch 31,
2025
2024
2025
2024
Gross profit
$4,139,506
$5,310,462
9,133,972
$8,158,999
Add: Depreciation and amortization
43,728
58,322
113,353
110,870
Add: Inventory provisions (reversals)
-
674,866
(114,645)
482,095
Adjusted Gross Margin
4,183,234
6,043,650
9,132,680
8,751,964
Adjusted Gross Margin (%)
55%
72%
58%
67%
The table below provides a reconciliation of net income under IFRS Accounting Standards in the unaudited condensed consolidated interim financial statements to Adjusted EBITDA for the three-month and six-month periods ended March 31, 2025, and 2024. Management believes that these non-GAAP measures are useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows to fund its cash requirements from period to period. The adjusting items below are considered to be outside of the Company's core operating results, and these items can distort the trends associated with the Company's ongoing performance, even though some of those expenses may recur.
Three months endedMarch 31,
Six months endedMarch 31
2025
2024
2025
2024
Net income
$429,139
$1,460,418
$1,635,185
$608,875
Add: Finance expense (gains)
(147,319)
22,340
(188,387)
12,376
Add: Depreciation and amortization
233,621
247,756
490,746
487,950
Add: Stock based compensation
65,540
81,464
156,063
197,393
Add: Inventory provisions (reversals)
-
674,866
(114,645)
482,095
Add: Impairment of intangible asset
-
101,577
-
176,025
Add: (Gain)/loss of finance lease receivable
-
-
149,690
(610,008)
Adjusted EBITDA
$580,981
$2,588,421
$2,128,650
$1,354,706
About Covalon
Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
(1)
See "Non-GAAP Measures" below, including for a reconciliation of the non-GAAP measures used in this release to the most comparable IFRS Accounting Standards measures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250528594851/en/
Contacts
To learn more about Covalon, please contact:Investor Relations, Covalon Technologies Ltd.Email: investors@covalon.com Website: https://covalon.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
KT&G will expand dividend schemes based on share repurchase, continuing growing dividend trend in line with profit
- Interim dividend raised by 200 KRW to 1,400 KRW—more resources for dividend based on higher profit and fewer outstanding shares - Major company that has maintained or increased dividend payout annually since listing, highly regarded for strong shareholder return programs SEOUL, South Korea, Aug. 21, 2025 /PRNewswire/ -- KT&G posted strong results on the 7th, with first half revenue exceeding 3 trillion KRW and revenue and operating profit recording third consecutive quarter of growth. Particularly, the global cigarette segment achieved five consecutive quarters of "triple growth" in revenue, operating profit, and sales volume. Revenue, sales volume, and adjusted operating profit each grew 30.6%, 9.1%, and 51.1% respectively, continuing the high-growth momentum. Furthermore, KT&G resolved to raise the interim dividend by 200 KRW to 1,400 KRW per share. Through the Q2 earnings report session, the company stated that it would reflect the dividend growth trend in its shareholder return program based on a comprehensive review of share repurchases & cancellation, profit growth, share prices, and other factors. Since its initial listing in 1999, KT&G has continued dividend payout for 26 consecutive years, either maintaining or increasing the amount every year. The recent three year's dividend per share trend is also a continuously growing one, with 5,000 KRW in 2022, 5,200 KRW in 2023, and 5,400 KRW in 2024. KT&G has yet again announced a raise in the interim dividend through the Q2 earnings report session, stating that it will continue to reflect the growth trend in its dividend policy. During the Q2 earnings report session held on the 7th, KT&G CFO Sang-Hak Lee stated that "the board resolved to raise the interim dividend by 200 KRW to 1,400 KRW—from 1,200 KRW last year—based on steady first half results," further stating "we will continue to make room for dividend growth through share repurchases and positively consider dividend payout linked to stock-price growth." He went on to further emphasize that "to the greatest extent possible, KT&G will reflect the dividend growth trend in its dividend policies considering Q3, Q4, and annual profit growth trends." Between 2024 to 2027, KT&G is implementing bold shareholder return policies to cancel 20% of issued shares (including newly repurchased shares). Accordingly, the number of outstanding shares continues to decline while the total annual dividend payout remains around 580 to 590 billion KRW, creating more room for per-share dividend growth. KT&G also announced its Double-Digit annual operating growth target during the earnings report session. Considering the decrease in dividend yield due to growing stock prices, the possibility of increased annual dividend per share is getting higher. The finance sector also foresees a sharp rise in dividends regarding KT&G's growing dividend trends. Through the report "Robust 2Q25; Higher dividend upside", Morgan Stanley analyst Kelly Kim projected that "as the management is taking dividend yield and rising earnings into consideration, we think there could be even further upside to our DPS assumption (W5,800)." (EoD) View original content to download multimedia: SOURCE KT&G Corporation Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
3 hours ago
- Business Wire
EverGen Infrastructure Reports Q2 2025 Results
VANCOUVER, British Columbia--(BUSINESS WIRE)-- EverGen Infrastructure Corp. ('EverGen' or the 'Company') (TSXV: EVGN) (OTCQB: EVGIF), today reported financial results as at and for Q2 2025. All amounts are in Canadian dollars unless otherwise stated and have been prepared in accordance with IFRS. Strategic & Financing Updates $5 Million Private Placement: In May 2025, EverGen completed a $5 million non-brokered private placement of common shares with Ask America, LLC strengthening the Company's balance sheet. Debt Refinancing: The Company progressed refinancing of its Fraser Valley Biogas facility, with a signed letter of intent for a $13 million debt facility and $250,000 operating line of credit in February. EverGen expects to complete this refinancing in Q3 2025, with terms that are better aligned with the Company's current operations and strategic focus. Additional Equity Financing: Commitments and indications received for up to $2 million of additional proceeds pursuant to a second tranche of the private placement of common shares at a price of $0.60 per share. The Company has extended this tranche to close alongside the debt refinancing, anticipated in Q3 2025. In all other respects, the terms of the private placement and use of proceeds will remain as previously disclosed in the April 23, 2025, press release. The completion of the private placement is subject to customary closing conditions, including the approval of the TSX Venture Exchange (the "Exchange"). Operational Updates RNG Production Growth: RNG production increased 17% year-over-year setting a new quarterly record. In March and April 2025, FVB achieved over 12,000 gigajoules ('GJs') of monthly production and is now approaching a run-rate equal to the annual nameplate capacity of the facility of 160,000 GJ. Optimization Initiatives: With planned changes to senior leadership team complete, the Company initiated optimization activities across core facilities during Q2 2025. While these activities temporarily reduce incoming organic waste volumes and revenues, they are expected to unlock sustainable cash flow, future growth and underpin EverGen's position as a long-term RNG leader. Financial Results: Management Commentary 'Q2 2025 was a transformational quarter for EverGen as we successfully recapitalized the business, aligned our leadership with a supportive lead investor, and continued to deliver record RNG production,' said Chase Edgelow, CEO of EverGen. 'We're tracking well against our 100-day plan for the business, and while optimization activities will continue to impact near term revenues, these initiatives are critical to positioning EverGen for scalable growth in 2026 and beyond, reinforcing our long-term vision as Canada's leading RNG infrastructure platform.' Outlook With a stronger balance sheet, growing RNG output, and optimization initiatives underway, EverGen is positioned to deliver sustainable growth, enhance shareholder value, and advance its leadership in Canada's RNG sector. The Company expects to complete its refinancing and additional equity raise in Q3 2025, further strengthening its financial foundation. For further information on the results please see the Company's Consolidated Financial Statements and Management's Discussion and Analysis filed on SEDAR+ at and on EverGen's website at EverGen will hold a results and corporate update conference call at 11:00 a.m. Eastern Time on Friday, August 22, 2025, hosted by Chief Executive Officer, Chase Edgelow. Find the latest Corporate Presentation in the Investor Center: Market Maker Further, to support liquidity and trading of the Company's shares, EverGen has engaged Independent Trading Group ('ITG'), Inc. to assist in maintaining active and orderly trading in the market for the common shares of the Company on the TSX Venture Exchange (the "TSX-V"). The market-making service will be undertaken by ITG in compliance with the applicable policies of the TSX-V and other applicable laws. For its services, the Company has agreed to pay ITG a service fee of $6,000 with option to renew monthly. The Company and ITG act at arm's length. ITG, nor any of its principals, currently own any securities, directly or indirectly, of the Company. The engagement of ITG is subject to the Company making certain filings with the Exchange and acceptance by the Exchange. About EverGen Infrastructure Corp. EverGen, Canada's Renewable Natural Gas Infrastructure Platform, is combating climate change and helping communities contribute to a sustainable future. Headquartered on the West Coast of Canada, EverGen is an established independent renewable energy producer which acquires, develops, builds, owns, and operates a portfolio of Renewable Natural Gas, waste to energy, and related infrastructure projects. EverGen is focused on Canada, with continued growth expected across other regions in North America and beyond. For more information about EverGen Infrastructure Corp. and our projects, please visit Non-GAAP Measures EverGen uses certain financial measures referred to in this press release to quantify its results that are not prescribed by IFRS. The terms EBITDA, adjusted EBITDA and working capital are not recognized measures under IFRS and may not be comparable to that reported by other companies. EverGen believes that, in addition to measures prepared in accordance with IFRS, the non-IFRS measurement provide useful information to evaluate the Company's performance and ability to generate cash, profitability and meet financial commitments. These non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for other measures of performance prepared in accordance with IFRS. EBITDA is defined as net income (loss) before interest, tax and depreciation and amortization. Adjusted EBITDA is EBITDA adjusted for share-based payment expenses, unusual or non-recurring items, contingent consideration gains and losses and non-controlling interests in adjusted EBITDA. Working capital is calculated as current assets less current liabilities. Forward-Looking Information This news release contains certain forward-looking statements and/or forward-looking information (collectively, 'forward looking statements') within the meaning of applicable securities laws. When used in this release, such words as 'would', 'will', 'anticipates', 'believes', 'explores', 'expects' and similar expressions, as they relate to EverGen, or its management, are intended to identify such forward-looking statements. More particularly, and without limitation, this press release contains forward looking statements and information concerning the Company's expectations regarding revenue growth and future financial or operating performance and the completion of a debt refinancing and a second tranche of the private placement, including the timing and amounts thereof. Such forward-looking statements reflect the current views of EverGen with respect to future events, and are subject to certain risks, uncertainties and assumptions., including the receipt of all approvals and satisfaction of all conditions to completion of the debt refinancing and the extension and completion of the private placement and the acceptance by the Exchange of the engagement of ITG. Many factors could cause EverGen's actual results, performance or achievements to be materially different from any expected future results, performance or achievement that may be expressed or implied by such forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits EverGen will derive therefrom, and accordingly, readers are cautioned not to put undue reliance on the forward-looking statements contained in this press release. The Company cautions that these forward-looking statements are subject to numerous risks and uncertainties, including but not limited to: counterparty risk to closing the debt refinancing and the second tranche of the private placement; the impact of general economic conditions in Canada, including the current inflationary environment; industry conditions including changes in laws and regulations and/or adoption of new environmental laws and regulations and changes in how they are interpreted and enforced, in Canada; volatility of prices for energy commodities; change in demand for clean energy to be offered by EverGen; competition; lack of availability of qualified personnel; obtaining required approvals of regulatory authorities in Canada; ability to access sufficient capital from internal and external sources; optimization and expansion of organic waste processing facilities and RNG feedstock; the realization of cost savings through synergies and efficiencies expected to be realized from the Company's completed acquisitions; the sufficiency of EverGen's liquidity to fund operations and to comply with covenants under its credit facility; continued growth through strategic acquisitions and consolidation opportunities; continued growth of the feedstock opportunity from municipal and commercial sources, and the factors discussed under 'Risk Factors' in the Company's Annual Information Form dated April 22, 2024, which is available on SEDAR+ at many of which are beyond the control of EverGen. Forward-looking statements included in this news release should not be read as guarantees of future performance or results. The forward-looking statements contained in this release are made as of the date of this release, and except as may be expressly required by applicable law, EverGen disclaims any intent, obligation or undertaking to publicly release any updates or revisions to any forward-looking statements contained herein whether as a result of new information, future events or results or otherwise. This news release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Business Wire
3 hours ago
- Business Wire
Abu Dhabi-based ADI Foundation Launches Testnet of ‘ADI Chain'
ABU DHABI, United Arab Emirates--(BUSINESS WIRE)--The ADI Foundation, an Abu Dhabi-based nonprofit organization dedicated to building the infrastructure nations trust and citizens deserve, today announced the public testnet of the ADI Chain. It is engineered to deliver sustainably high throughput with ultra-low transaction fees by utilizing AI-assisted protocol automation with GPU acceleration to unlock real-time intelligence, dynamic network adaptation and efficiency. This chain's novel technology will enable developers to build responsive, client-side applications with near real-time settlement. ADI Foundation will continue expanding node infrastructure, onboarding ecosystem partners, and supporting priority use cases across the UAE and emerging markets. 'Over the past decade, the benefits of the web3 adoption have been concentrated in relatively few verticals of the economy," said Andrey Lazorenko, CEO of ADI Foundation. 'Launching the testnet is an important step towards realizing Abu Dhabi's vision for trusted, high-performance digital infrastructure. With GPU computing and AI-engineered protocol design at its core, ADI Chain will provide enterprise-grade infrastructure for scaling ecosystem partners which will support our mission in bringing 1 billion new users onchain by 2030.' ADI Chain was built to bridge the gap between compliance and innovation. Currently, many chains are unable to meet stringent government standards, which leaves many governments unable to deploy technology quickly and replace antiquated systems. ADI Chain is a compliance-native L2, which enables governments and regulated institutions to launch stablecoins, health systems, land registries and payment rails without sacrificing speed, efficiency, security or regulatory compliance. ADI Chain aims to serve as the backbone for digital services across finance, identity, healthcare, sustainability, and other real-world sectors, starting with its integration into the Dirham-backed stablecoin project being developed in collaboration with leading UAE institutions including FAB, ADQ, and IHC, and to be regulated by the Central Bank of the UAE. The testnet is open to all developers who want to test ADI Chain's capabilities and help optimize the network prior to its mainnet deployment. To access ADI Chain's testnet environment, please visit the ADI Testnet Explorer. Notes For Editors: About ADI Foundation ADI Foundation is an Abu Dhabi-based non-profit organization founded by Sirius International Holding (a subsidiary of IHC), dedicated to empowering governments and institutions in emerging markets through blockchain infrastructure and partnerships needed to unlock sovereign digital economies and drive large-scale social and economic inclusion. Its mission is to bring 1 billion people into the digital economy by 2030, building on a strong foundation of 400+ million people already within its reach. Through strategic partnerships in over 20 countries and a growing portfolio of use cases such as a new UAE stablecoin backed by Dirhams, ADI is redefining what is possible at the intersection of technology and impact. Positioned in Abu Dhabi, which is rapidly emerging as the Silicon Valley of inclusive tech-finance, ADI Foundation is proud to lead the transformation by turning visionary policy into practical, scalable systems that empower people, businesses, and governments alike. For more information, visit:
